Gary J. Weil, MD
Professor, Departments of Medicine and Molecular Microbiology
- BA: Harvard College, Boston, MA (1971)
- Medical Degree: Harvard Medical School, Boston, MA (1975)
- Residency, Internal Medicine: Yale-New Haven Hospital, New Haven, CT (1978)
- Research Associate, Laboratory of Parasitic Diseases: NIAID, Bethesda, MD (1981)
- Fellowship, Infectious Diseases: Washington University School of Medicine, St. Louis, MO (1982)
- Internal Medicine
- Infectious Disease
- Clinical Tropical Medicine and Traveler's Health, (ASTMH)
Dr. Weil and Dr. Ramakrishna Rao, PhD, associate professor of medicine, are recipients of the 2016 Anne Maurer-Cecchini Award, which recognizes outstanding epidemiological or clinical research on neglected tropical diseases, given at the Geneva Health Forum in April 2016.
Infectious diseases, tropical medicine.
My laboratory conducts research on filarial nematode parasites that cause important tropical diseases such as lymphatic filariasis and river blindness. Our work is focused on the development and field application of improved diagnostic tests, on developing improved therapies, and on basic parasite biology. For example, we have collaborated on the development of new diagnostic tests for filariasis based on detection of parasite antigens, parasite DNA, and human antibodies to recombinant parasite antigens. Ongoing field studies are exploring the value of these newer tests for monitoring the impact of mass treatment programs on filariasis prevalence rates and transmission. Basic research in the laboratory is currently focused on studies of filarial parasite gene expression across the life cycle and in response to stresses such as drug treatment and radiation. We are also studying the role of Wolbachia (endosymbiotic bacteria) on filarial worm survival and development.
The DOLF project (funded by the Bill and Melinda Gates Foundation) supports applied field research in seven countries. This exciting project pools the talent and experience of outstanding scientists from the North and South so that they can work together toward a lofty goal, namely a world without lymphatic filariasis or onchocerciasis.
Fischer PU, Weil GJ. North American Paragonimiasis: Epidemiology and diagnostic strategies. Expert Rev Anti Infect Ther 2015:13:779-786.
Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. Plos Negl Trop Dis 2017;11:e0005163.
Rao RU, Samarasekera SD, Nagodavithana KC, Dassanayaka TD, Punchihewa MW, Ranasinghe US, Weil GJ. Reassessment of areas with persistent lymphatic filariasis nine years after cessation of mass drug administration in Sri Lanka. Plos Negl Trop Dis 2017, in press.
Andersen BJ, Kumar J, Curtis K, Sanuku N, Satofan S, King CL, Fischer PU, Weil GJ. Changes in cytokine, filarial antigen, and DNA levels associated with adverse events following treatment of lymphatic filariasis. Clin Infect Dis 2017, in press.